trial with title PILOT - B cell non-Hodgkin lymphoma - TRANSCEND-PILOT-017006 - US

*NOTE - some study locations are open, while others remain temporarily closed due to the impact of Coronavirus (COVID-19)*

If you are interested in taking part in this study, begin typing your location below and then select from the drop-down list. The map will update with sites within the selected distance and a list of locations will appear below.

Please note, the map below only lists study sites that are accepting online referrals. If you cannot find a site in your area, please check back again as study sites can be added to the study on an ongoing basis.

Alternatively, if you wish to see the full listing of all study sites, visit clinicaltrials.gov.

Select Country

Site Name Address Status Distance
Levine Cancer Institute
1021 Morehead Medical Drive
Charlotte, NC, 28204
United States
Not Recruiting --
Northwestern University
675 North Saint Clair Street
Chicago, IL, 60611
United States
Recruiting --
Regional Cancer Care Associates
Brier Hill Court, Bldg. J2
East Brunswick, NJ, 08816
United States
Recruiting --
Banner MD Anderson Cancer Center
2940 East Banner Gateway Drive
Gilbert, AZ, 85234
United States
Recruiting --
Northwest Medical Specialties
1624 South I Street
Tacoma, WA, 98405
United States
Not Recruiting --
Earle A. Chiles Research Institute
4805 Northeast Glisan Street
Portland, OR, 97213
United States
Recruiting --
USOR - Prisma Health System - Eastside Cancer Center
65 International Drive
Greenville, SC, 29615
United States
Recruiting --
Oncology Hematology Care
4725 East Galbraith Road Suite 320
Cincinnati, OH, 45236
United States
Recruiting --
New York Oncology Hematology - Albany Cancer Center
43 New Scotland Ave.
Albany, NY, 12208
United States
Recruiting --
The Blood and Marrow Transplant Group of Georgia
5670 Peachtree Dunwoody Rd # 1000
Atlanta, GA, 30342
United States
Recruiting --
Intermountain Healthcare- LDS Hospital
8th Ave and C Street
Salt Lake City, UT, 84143
United States
Recruiting --
University of Texas Southwestern Medical Center
5323 Harry Hines Blvd
Dallas, TX, 75390
United States
Recruiting --
University of Kentucky
800 Rose Street
Lexington, KY, 40536
United States
Recruiting --
Stanford Cancer Genetics Clinic
875 Blake Wilbur Drive
Stanford, CA, 94304
United States
Recruiting --

More about Study Participation

Participation in the PILOT Study lasts approximately two years and includes:

• A screening period that will last up to 14 days, during which your eligibility to participate in the PILOT Study will be confirmed. If you are determined to be eligible, your T cells will be removed (through leukapheresis) and the investigational study treatment will be manufactured. This will take approximately four weeks, but timing varies from patient to patient.
• A pretreatment period that will occur up to seven days before the treatment period. During this time, the study doctor will reconfirm that you are eligible for study participation.
• A treatment period, which will last approximately 35 days.
         o You will receive an infusion one time, after which you will be closely monitored for side effects for the next 30 days.
         o During this time, you will receive three days of conditioning chemotherapy followed by an infusion of the investigational study treatment
• A posttreatment period, during which you will visit the study site at least eight times before your participation in the study ends. This period will last 23 months.

After completion of two years of assessments in this study, an optional long-term follow-up study for survival, long-term toxicity, and safety will continue as a separate study for up to 15 years after administration of JCAR017 investigational study treatment.

The investigational study treatment used in the PILOT Study is called JCAR017. This drug is the result of a modification to a participant’s own immune cells (T cells) with a chimeric antigen receptor (CAR). These modified T cells, (CAR T cells) may attack the cancer cells and other cells. JCAR017 is administered once as an infusion during the treatment period. As with any medicine, JCAR017 may have side effects. As an investigational study treatment, not all the side effects may be known at this time. Two of the primary side effects that you will be monitored for include cytokine release syndrome and neurotoxicity.